Miransertib

Miransertib · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Miransertib, covering 2023-03-31 to 2025-02-07. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) [Phase 2]

See pricing